People: GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,385.00GBp
24 Dec 2014
Price Change (% chg)

0.00p (+0.00%)
Prev Close
1,385.00p
Open
1,377.00p
Day's High
1,389.50p
Day's Low
1,362.50p
Volume
2,301,306
Avg. Vol
9,636,299
52-wk High
1,709.00p
52-wk Low
1,296.50p

Search Stocks

Slaoui, Moncef 

Brief Biography

Dr. Moncef Slaoui is Chairman, Executive Director of GlaxoSmithKline PLC. Dr. Slaoui continue to provide scientific and technical counsel on pharmaceutical R&D activities to the CEO and Board. Dr. Slaoui joined GSK Vaccines in 1988 where he engineered the development of a robust vaccines pipeline. He then led Worldwide Business Development for pharmaceutical products before his appointment to lead R&D in 2006. He was also given overall responsibility for GSK’s Oncology Business in 2010; for GSK Vaccines in 2011; and for all Global Franchises in 2012. He has a PhD in Molecular Biology and Immunology from Université Libre de Bruxelles and has published more than 100 scientific papers and presentations. Prior to joining GSK, Moncef was Professor of Immunology at the University of Mons, Belgium. He is a member of the PhRMA and the Biotechnology Industry Organization boards in the USA and a member of the Advisory Committee to the Director of National Institutes of Health. He is also an adviser to the Qatar Foundation, and a member of the Qatar Biomedical Research Institute Scientific Advisory Committee. Moncef has advised the US President’s Council of Advisors on Science and Technology and he was a member of the Board of the Agency for Science, Technology & Research (A*STAR) until January 2011.

Basic Compensation

Total Annual Compensation, GBP Long-Term Incentive Plans, GBP All Other, GBP Fiscal Year Total, GBP
3,900,000 4,248,000 266,000 8,414,000

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Christopher Gent

734,000

Andrew Witty

7,207,000

Simon Dingemans

3,292,000

Moncef Slaoui

8,414,000

Deirdre Connelly

--

Roger Connor

--
As Of 30 Dec 2013
Search Stocks